Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Oct 15, 2021 1:02pm
244 Views
Post# 34010505

RE:RE:RE:RE:RE:RE:LOL

RE:RE:RE:RE:RE:RE:LOLThink you saw me on CEO yesterday - I didn't disappear.
What do you think ... I retreated to the "layer" to watch from the control panel ?
Don't be rediculous.

I've been here less over the past few months as some people are hard to take - better that way.

But ... I have been saying the company has options ... and ... they are using those options.

There also seems to be some new information regarding liver that they acted on - no one here was prepared for that.

If you want to take out your anger on someone - I suggest you do it with the company.



StockingUp21 wrote:

what ru talking about elsewhere. You disappear yesterday and today after fighting every bad comment here for months,years even. I remember you do the same august 3

 

MrMugsy wrote: Sus?  Really ?

Had to go back and see what you're talking about and it seems that Stockingup was wondering where a few people were ... yet ... I commented on his stuff elsewhere.  I hope he's not talking about me.

My take?  Not written very well. 

Heading towards acute - makes sense - they have options - that's one of them.
Need more details on timing.

No real details on the chronic pain side - is lower dose still an option?  what are alternative treatment regimens?  Vague.

What is this new indication with high unmet need for ATB-352?  What does harmonizing mean?  Again, vague.

Issues with the 75mg cohort - that news to me.  

Guessing they got some direction from the liver specialsist and this is what they decided on strategically.

That's all I have right now - more questions than answers. 




 

 

Inthepez wrote: It’s looking pretty sus that you’re commenting now mugsy.

What’s your take on all this? 


MrMugsy wrote:
SouthernTierTom wrote: When there is a program in place, the IDs are all interchangable. Chances are strong you are Mugs

Even the naive recognize these bullboard dramas

 


Hey - that's not fair ... I don't want to be associated with him.

: )

 

 




<< Previous
Bullboard Posts
Next >>